Cartesian Therapeutics (RNAC) Cash from Operations (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Cash from Operations data on file, last reported at 22135000.0 in Q1 2026.

• On a quarterly basis, Cash from Operations rose 4.21% year-over-year to 22135000.0 in Q1 2026; TTM through Mar 2026 was 72968000.0, a 136.41% decrease from a year earlier, with the FY2025 full-year figure at 73941000.0, down 212.33% from the prior year.
• Cash from Operations for Q1 2026 stood at 22135000.0, down from 17712000.0 in the prior quarter.
• Over the last five years, Cash from Operations for RNAC reached as high as 13691000.0 in Q3 2024 and fell as low as 23286000.0 in Q4 2023.
• Historically, Cash from Operations has averaged 11914235.29 across 5 years, with a median of 12271000.0 in 2022.
• Across the five-year window, Cash from Operations plunged 311.69% in 2023 and surged 248.57% in 2024, its largest moves.
• Year by year, Cash from Operations stood at 11849000.0 in 2022, then sank by 96.52% to 23286000.0 in 2023, then surged by 69.93% to 7002000.0 in 2024, then slumped by 152.96% to 17712000.0 in 2025, then decreased by 24.97% to 22135000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 22135000.0 in Q1 2026, 17712000.0 in Q4 2025, and 15600000.0 in Q3 2025.